CVI Accepted Manuscript Posted Online 19 July 2017 Clin. Vaccine Immunol. doi:10.1128/CVI.00194-17 Copyright © 2017 American Society for Microbiology. All Rights Reserved.

- 1 Title: Assignment of weight-based antibody units for four additional serotypes to a human anti-pneumococcal
- 2 standard reference serum 007sp
- 3
- 4 Running Title: Pneumococcal Reference Serum
- 5
- 6 Goldblatt D^{1#}, McKeen A², Burbidge P¹, McElhiney S², McLaughlin, L², Johnson A², Rauh M³, Giardina PC²
- 7
- 8 1 University College London Great Ormond Street Institute of Child Health, London, UK
- 9 2 Pfizer Vaccine Research and Development, USA
- 10 3 Universitätsklinikum Erlangen, GER
- 11

Downloaded from http://cvi.asm.org/ on July 28, 2017 by UC London Library Services

Immunology

12

- 13 Corresponding Author#:
- 14 Professor David Goldblatt,
- 15 Professor of Vaccinology and Immunology,
- 16 Immunobiology Section,
- 17 Great Ormond Street Institute of Child Health
- 18 University College London,
- 19 30 Guilford Street,
- 20 London WC1N 1EH,
- 21 United Kingdom.
- 22 Direct Telephone: +44 (0)20 7905 2886,
- 23 Fax: +44 (0)20 7905 2882,
- 24 Email: d.goldblatt@ucl.ac.uk
- 25
- 26 Word count
- 27 Abstract: 247
- 28 Body: 2529
- 29

30

31	Abstract

32	The pneumococcal ELISA reference standard serum, Lot 89SF, has been in use since 1990 and was replaced with
33	a new reference standard serum, 007sp in 2013. This serum was generated under an FDA-approved clinical
34	protocol, where 278 adult volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine,
35	Pneumovax II [®] , and a unit of blood was obtained twice within 120 days following immunization. Pooled serum
36	was prepared from the plasma, filled at 6ml per vial and lyophilised. Five independent laboratories participated
37	in bridging the serotype specific IgG assignments for 89SF to 007sp to establish equivalent reference values for
38	13 pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) using the WHO reference
39	ELISA. A subsequent follow up study established equivalent reference values for an additional seven serotypes
40	(8, 10A, 11A, 12F, 15B, 22F, 33F). In this study three laboratories assigned weight-based IgG concentrations in
41	mcg/mL of serum to 007sp for four additional serotypes; 2, 9N, 17F and 20A. This study completes the
42	assignment of serotypes in 89SF to 007sp. In addition, the IgG antibody assignments for a 12 member WHO QC
43	serum panel were extended to cover the four additional serotypes. Agreement was excellent with a
44	concordance correlation coefficient (r_c) > 0.996 when each laboratory was compared to the assigned values for
45	the 12 WHO QC sera. The 007sp preparation has replaced 89SF as the pneumococcal reference standard.
46	Sufficient quantities of 007sp are projected to be available for the next 25 years.

47 Introduction

48 A Streptococcus pneumoniae Human Reference Serum, lot 89SF, greatly facilitated the standardization of ELISA 49 methodologies during a critical period when the first pneumococcal polysaccharide-conjugate vaccines were being evaluated for licensure. The standard serum was used in serotype specific ELISAs designed to measure 50 51 IgG antibody specific for individual pneumococcal capsular polysaccharides. Serotype specific weight-based values for IgG, IgA and IgM were originally derived for serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for 52 Lot 89SF by Quateart, et al.¹. Assignments for the additional serotypes in the 23-valent pneumococcal 53 polysaccharide vaccine were subsequently bridged from the assignments for the original 11 serotypes². Due to 54 dwindling supplies of 89SF, a new reference standard serum, 007sp, was developed and described in 2011³. 55 56 This serum was generated under an FDA-approved clinical protocol, where 278 adult volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine, Pneumovax II®, and a unit of blood was 57 58 obtained twice within 120 days following immunization. Pooled serum was prepared from the plasma, filled at 6ml per vial and lyophilised. Five independent laboratories participated in bridging the serotype specific IgG 59 60 assignments for 89SF to the new reference serum, 007sp to establish equivalent reference values for 13 pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) using the WHO reference 61 ELISA³. This serum has replaced 89SF (which is no longer distributed) and been routinely used in pneumococcal 62 assays around the world for the past several years. 63

With the ongoing requirement to evaluate Pneumovax II[®] and the development of additional extended valency conjugate vaccines, it has been imperative to assign values to 007sp for additional serotypes. In a three-centre study we recently assigned to 007sp the IgG antibody values in mcg/mL to seven additional pneumococcal serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F)⁴. This report describes the efforts undertaken by the same three laboratories to establish the serotype specific IgG concentrations for 007sp to the final four remaining

serotypes in 89SF currently unassigned in 007sp (2, 9N, 17F, and 20A), and to assign values to a set of 12 69 70 existing World Health Organisation (WHO) Quality Control (QC) sera for the additional serotypes.

71

72

73 Results

To assess the consistency among the laboratories, the mean of the log IgG antibody concentrations of 007sp for 74 each serotype (2, 9N, 17F, and 20A) was calculated for each laboratory and used to assess the level of 75 76 agreement among the laboratories. There was a high level of agreement with the concordance correlation 77 coefficient r_c exceeding 0.95 for all plots. For the same data, the Pearson correlation coefficient was \ge 0.999, indicating excellent precision, and the accuracy coefficent (C_a) was ≥ 0.95 in each case. Analysis of variance 78 79 (ANOVA) models were used to estimate IgG antibody concentrations for each of the serotypes in 007sp. Final 80 point estimates and confidence intervals were obtained by back-transforming the estimated log-transformed concentrations and associated 95% confidence intervals. These estimated IgG antibody concentrations are the 81 82 "assigned" values for each serotype (2, 9N, 17F, and 20A) in 007sp and are shown in Table 1. These values were derived by the double absorption of 007sp with both mono-substituted and di-substituted cell wall 83 polysaccharide (CPS)⁵⁻⁷, and thus in the future, when used as a reference standard serum, both standard and 84 unknown test samples should be double absorbed. The IgG antibody concentrations assigned to 007sp 85 compared to the original values assigned to 89SF are shown in Figure 1. 86

87

88 Serum IgG antibody concentrations against serotypes 2, 9N, 17F, and 20A were determined for the 12-member WHO QC serum panel using both 89SF and 007sp as the reference standards. Table 2 presents the assigned 89 90 values for the QC serum panel (n≥27 for each estimate) while Figures 2 and 3 display the scatter plots and box

plots for the four serotypes analyzed. These plots illustrate the agreement of the four estimated assigned IgG values for 007sp compared to Lot 89SF for each WHO QC serum and serotype. The scatter plots (Figure 2) show the high degree of agreement and correlation among the calculated (log) IgG concentrations for the panel of 12 WHO QC sera using 007sp (vertical scale) vs. Lot 89SF (horizontal scale) as reference standards. A perfect level of agreement would yield a straight line with slope of one and intercept at zero, and all data points cluster tightly about this line of identity. Laboratories 1 and 3, which both used

automated liquid-handling robotics to perform the assays, showed a slightly lower degree of scatter around the line of identity compared to Laboratory 2, which used a manual assay process. The box plots (Figure 3) illustrate the deviation of the 007sp-based estimates from those obtained using Lot 89SF as reference standard

100 for the 12 WHO QC sera. The IgG concentrations calculated using 007sp as reference standard are largely within 101 two fold (1/2 - 2.0) of those calculated using lot 89SF as reference standard.

102

91

92

93

94

95

96

97

98

99

Table 3 presents the accuracy coefficient (C_a), Pearson correlation coefficient (r), and concordance correlation 103 104 coefficient (r_c) which are measures of agreement between pairs of laboratories and between laboratories and 105 consensus ELISA concentrations for the WHO QC sera. To form paired data between the labs for these 106 comparisons, the serotype-specific replicate IgG antibody concentration values generated in each laboratory were replaced by a single predicted value obtained from a mixed-model analysis of variance. There was an 107 108 exceptionally high degree of agreement with all values \geq 0.99.

109

110 Discussion

In this study, we describe the assignment of IgG antibody concentrations in weight-based microgram per 111

milliliter units to the human anti-pneumococcal standard reference serum 007sp and a panel of 12 112

S

Downloaded from http://cvi.asm.org/ on July 28, 2017 by UC London Library Services

113	pneumococcal QC sera for the final four additional serotypes originally calculated and assigned to 89SF. This
114	new standard was developed in 2009/10 and was required to replace limited stocks of the original standard
115	serum Lot 89SF. Assignment for additional serotypes are required as the original standard, Lot 89SF, which had
116	values assigned for the 23 serotypes in Pneumovax II [®] , is no longer available (007sp is exclusively distributed via
117	FDA). However studies evaluating Pneumovax II [®] are still undertaken and new conjugate vaccines are currently
118	under development incorporating additional serotypes found in Pneumovax II®, but not in existing PCV's.
119	Assignment of the weight-based antibody concentrations to human anti-pneumococcal standard reference
120	serum 007sp was originally performed for the 13 serotypes represented in currently licensed conjugate
121	vaccines (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) ³ . Using established laboratories and a well
122	characterized ELISA procedure ^{8,9} that was followed by all participating laboratories, it was possible to assign
123	weight-based units to 007sp by running 007sp alongside a standard curve of 89SF and treating 007sp as the
124	unknown. Very high levels of agreement between the participating laboratories for the weight-based units of
125	IgG specific for 13 serotypes in 007sp were achieved. Having accepted concentration values for an existing
126	standard has significantly simplified the assignment process. Subsequently we undertook a further assignment
127	exercise utilizing the expertise of three laboratories. Values (mcg/ml) for IgG specific to seven additional
128	serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) were assigned to 007sp and the 12 QC sera described above ⁴ .
129	As in the original assignment study, we have now assigned values (mcg/ml) for IgG specific for the final four
130	serotypes in 89SF that remained unassigned (2, 9N, 17F and 20A). We were able to further validate the values
131	obtained and the performance of 007sp as a standard during the process of assigning serotype specific IgG
132	values (mcg/ml) to a panel of 12 WHO QC sera previously prepared from the sera of pneumococcal
133	polysaccharide vaccinated adults. Concordance was high among laboratories (Table 3) and between results for
134	laboratories and consensus ELISA concentrations. With the adherence to the uniform application of the WHO

ELISA⁹ in the present study, we were able to achieve high levels of precision and accuracy in the values assigned
to the additional four serotypes of 007sp and the WHO QC sera.

137 ANOVA mixed modeling is a flexible framework that allows estimation of ELISA concentrations for 007sp and

the 12 WHO QC sera for each serotype by laboratory. These models may be used to compare and contrast

139 results within and among laboratories. Random-effects ANOVA models allowed us to reduce the replicate

140 measurements to a single predicted value which were then used to measure levels of consistency among the

141 laboratories. While we were able to estimate serotype-specific concentrations for 007sp through a bridge to

142 89SF (Table 1), the actual ELISA concentrations for the WHO QC sera used in this study were unknown, so it was

143 not possible to compare "true" values. The ANOVA mixed model provided a mechanism for estimating

144 consensus values, which served as assigned values for these sera (Table 2).

145 Establishing a new reference serum for the pneumococcus was essential for ongoing efforts to evaluate new

pneumococcal vaccines and to maintain the link with the original serology performed as part of the pivotal

147 efficacy studies conducted prior to licensure. The high degree of agreement between the 007sp-based and lot

148 89SF-based estimates in the original assignment exercise³ has inspired confidence in the validity of the 007sp

assignments. In this follow on study, a similar high level of agreement has been observed.

150 The new standard, 007sp, now has assigned values for the 24 pneumococcal serotypes currently contained in

151 licensed vaccines, is available in large quantities and should provide continuity for the foreseeable future. Its

152 performance in ELISA suggests that it is unlikely to affect the operation of validated assays currently established

in serology laboratories. Details of how to obtain 007sp and the QC sera are available at

154 <u>https://www.vaccine.uab.edu/</u>.

155

156 Materials and Methods

The collection and processing of sera has been described in detail in a previous manuscript ³ . Briefly, 278
volunteers were vaccinated once with Pneumovax II [®] , and serum collected on two occasions post vaccination.
Serological and virological testing showed sera to be free from Hepatitis B and C virus, syphilis and HIV. Sera
from 262 volunteers were pooled and then aliquoted at 6 ml per vial and lyophilised while sera from the
remaining 16 donors were separately aliquoted to create a new panel of individually calibrated sera for use in
functional assays.
An existing WHO QC serum panel, established by D. Goldblatt (UCL Institute of Child Health) previously by
immunizing adults with pneumococcal polysaccharide vaccine, and distributed by the National Institute for
Biological Standards and Control (NIBSC; Potters Bar, Hertfordshire, United Kingdom), was supplied for
assigning serotype-specific IgG assignments for the 12 QC serum panel members.
Laboratory Methods
Laboratory Methods Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen, Germany). Two of the three laboratories used
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen, Germany). Two of the three laboratories used liquid-handling robotics to perform various aspects of the ELISA while the other laboratory performed the
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen, Germany). Two of the three laboratories used liquid-handling robotics to perform various aspects of the ELISA while the other laboratory performed the assays by hand. The assignment of weight-based units followed the protocol established for the initial
Three laboratories participated in the assignment (In alphabetical order: Institute of Child Health, University College London, London, United Kingdom; Pfizer Vaccine Research and Development, Pearl River, NY; and Universitätsklinikum Erlangen Kinder- und Jugendklinik, Erlangen, Germany). Two of the three laboratories used liquid-handling robotics to perform various aspects of the ELISA while the other laboratory performed the assays by hand. The assignment of weight-based units followed the protocol established for the initial assignment, which can be found under the reference materials section at <u>http://www.vaccine.uab.edu</u> and

Downloaded from http://cvi.asm.org/ on July 28, 2017 by UC London Library Services

conditions using the standardized pneumococcal reference ELISA (the "WHO ELISA")^{8,9}. The ELISA protocol

Accepted Manuscript Posted Online

179	followed by participating laboratories can be found at <u>http://www.vaccine.uab.edu/ELISA%20Protocol.pdf</u> . The
180	only deviation from the WHO protocol is that double absorption of 007sp with cell wall polysaccharide (CPS) ⁵
181	was undertaken using two absorbents prepared from un-encapsulated S. pneumoniae mutant strains
182	incorporating both mono- and di-substituted CPS ^{7,8} rather than CPS and purified 22F capsular polysaccharide.
183	Lot 89SF had a value assigned for Serogroup 20, the serogroup included in Pneumovax 23 [®] . This sugar has now
184	been identified as serotype 20A ¹⁰ so this capsular polysaccharide and nomenclature has been used in this
185	assignment exercise. Briefly, four independent sets of serial dilutions of lot 007sp (supplied by CBER, FDA) were
186	made from four independent serum vials. The four sets of eight serial dilutions were run in duplicate as
187	unknown samples on each ELISA plate in a 10-plate replicate series to generate approximately 40 data points
188	per serotype for 007sp from each of the participating laboratories. Each plate also contained seven serial
189	dilutions of lot 89SF run in duplicate and quality control serum. The ELISA procedure was carried out for each
190	serotype, and the raw optical density measurements were sent to Pfizer's testing laboratories for analysis.
191	In the second phase of the study, a panel of 12 existing WHO quality QC was assayed and quantified using both
192	007sp and 89SF as reference standards. Three WHO QC sera, as well as 007sp and 89SF, were run in duplicate
193	on each ELISA plate yielding up to 10 independently determined QC values for each sample and serotype from
194	each laboratory over a minimum of 5 days. The performance of 007sp was assessed by comparing calculated
195	concentrations using 007sp to those using 89SF as the reference standard.
100	

196

197 Statistical Analysis:

During each phase of the study and the selected repeated assays, there were about 40 determinations of IgG antibody concentrations for 007sp for each serotype from each laboratory. IgG antibody concentrations were estimated for the four serotypes using a linear mixed-effects analysis of variance (ANOVA) model. All models

S

Clinical and Vaccine mmunology

were fit independently by serotype and included laboratory and batch as random effects. Confidence intervals 201 202 (95% CI) were estimated by serotype, accounting for the variance components between the laboratories, 203 between batches within a laboratory and residual variability. Data were analyzed after (common) log transformation of ELISA IgG concentrations. The means of the log concentrations for each serotype were 204 205 calculated for each laboratory and used to assess agreement and precision among the three laboratories. Agreement is defined as the closeness of the (log) concentration between two laboratories for each of the four 206 serotypes and is measured using Lin's concordance correlation coefficient (r_c), which is a combination of Lin's 207 coefficient of accuracy $(C_a)^{11}$ and Pearson's correlation coefficient (r). 208

209

210 Once the four antigen-specific IgG concentration estimates for 007sp were finalized, IgG concentrations were determined for 12 samples from the WHO QC serum panel. Through the two phases of the study, each 211 212 laboratory contributed up to ten IgG concentration estimates for each WHO QC sample for each serotype. The 12 WHO QC samples do not have known ELISA concentrations or assignments for serotypes 2, 9N, 17F and 20A, 213 214 and hence, "consensus" ELISA IgG concentration values were estimated using an analysis-of-variance (ANOVA) 215 mixed-effects model from the present data. Scatter plots and boxplots were employed to assess and evaluate 216 the ability of the three laboratories to produce consistent estimates of antibody concentrations for each 217 serotype in 007sp.

218

Acknowledgements 219

220 This paper is dedicated to the memory of Dr Milan Blake who initiated the 007sp development in 2006, but 221 tragically died unexpectedly prior to the project's completion. The authors would like to thank Charles Y Tan, 222 Senior Director, Pfizer Biotechnology Clinical Development Statistics, for statistical support. DG's laboratory

223 receives research and contract support for serology from Merck, Sanofi Pasteur and GSK. DG participates in

- occasional technical advisory boards and provides advice to GSK, Sanofi Pasteur and Merck and is a National 224
- 225 Institute for Health Research (NIHR) Senior Investigator. AM, SM, LM, AJ and PG are employees of Pfizer.

227 References

Quataert SA, Kirch CS, Wiedl LJ, Phipps DC, Strohmeyer S, Cimino CO, Skuse J, Madore DV. 1995. Assignment of
 weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. ClinDiagnLab Immunol
 2:590-597.

Quataert SA, Rittenhouse-Olson K, Kirch CS, Hu B, Secor S, Strong N, Madore DV. 2004. Assignment of weight based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(<u>F).</u> ClinDiagnLab
 Immunol 11:1064-1069.

234 3. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I,

235 Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Lin J, Maisonneuve J, Nahm M, Raab J, Romero-Steiner

236 S, Rose C, Schmidt D, Stapleton J, Carlone GM. Establishment of a new human pneumococcal standard reference serum,

237 007sp. *Clinical and vaccine immunology : CVI* 2011; **18**(10): 1728-36.

238 4. Goldblatt D, Tan CY, Burbidge P, McElhiney S, McLaughlin L, Tucker R, Rauh M, Sidhu M, Giardina PC. Assignment of

239 weight-based antibody units for 7 additional serotypes to a human anti-pneumococcal standard reference serum 007sp.

240 Clin Vaccine Immunol. 2015 Sep 9. pii: CVI.00437-15. 5. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide

241 absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

242 *ClinDiagnLab Immunol* 2001; **8**(2): 266-72.

243 6. Strong NM; Quataert SA ZN, Koster M, Madore DV. Comparison of pneumococcal absorbent preparations used in

244 Human Anti-Pneumococcal Polysaccharide (PNPS) Antibody (AB) ELISAs. *Pediatr Res* 1996; **39**: 186.

245 7. Karlsson C, Jansson PE, Skov Sorensen UB. The pneumococcal common antigen C-polysaccharide occurs in

different forms. Mono-substituted or di-substituted with phosphocholine. Eur J Biochem 1999; 265(3): 1091-7.

247 8. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quateart SA, Hildreth S,

248 Sikkema DJ, Kayhty H, Jonsdottir J, Nahm M. Enzyme-linked immunosorbent assay for quantitation of human antibodies

to pneumococcal polysaccharides. *ClinDiagnLab Immunol* 2003; **10**(4): 514-9.

250	9. Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, Giebink GS, Jonsdottir I, Kayhty H, Konradsen HB,
251	Madore DV, Nahm MH, Schulman CA, Holder PF, Lezhava T, Elie CM, Carlone GM. An analytical model applied to a
252	multicenter pneumococcal enzyme-linked immunosorbent assay study [In Process Citation]. J ClinMicrobiol 2000; 38(6):
253	2043-50.
254	10. Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, Nahm MH. Biochemical, genetic, and
255	serological characterization of two capsule subtypes among Streptococcus pneumoniae Serotype 20 strains: discovery of
256	a new pneumococcal serotype. J Biol Chem. 2012 Aug 10;287(33):27885-94. doi: 10.1074/jbc.M112.380451.
257	11. Lin LI. A concordance correlation coefficient to evaluate reproducibility. <i>Biometrics</i> 1989; 45 (1): 255-68.
258	
259	
260	
261	Figure Legends:
262	
263	Figure 1: Comparison of the original assigned values for four serotypes in 89SF with those assigned to 007sp.
264	
265	Figure 2: Scatter plots showing the correlation among the derived concentrations for the panel of 12 WHO QC
266	sera using 007sp (vertical scale) vs. 89SF (horizontal scale) as reference standards for the four serotypes
267	analysed (N=>8 for each for the 12 QC serum from each laboratory).
268	
269	Figure 3: Box plots illustrating the deviation of the 007sp estimates from those obtained using 89SF for the four
270	serotypes of the panel of 12 WHO QC sera analysed (N≥8 for each QC serum from each laboratory; N _{total} ≥108).
271	In these plots, the box is defined by the 25th and 75 th percentiles of the distribution; the line within the box
272	represents the median or 50th percentile. Vertical lines extend to the most extreme observation that is less

S

273 than 1.5 times the interquartile range (75th to 25th percentiles), solid circles correspond to individual assay values which are progressively distant from the bulk of the data. Data above the horizontal line of 1 on the 274 275 vertical axis indicates 007sp estimates are greater than estimates using Lot 89SF. On the vertical axis, 2 indicates a point where the 007sp estimate was twice the 89SF estimate. A value of 1/2 indicates the 89SF 276 277 estimate was two times the 007sp estimate. Boxes centered on the horizontal line of 1 indicate a good 278 agreement between the 007sp and 89SF estimates. 279

S

281

Table 1. Assigned IgG antibody concentrations (mcg/ml) for 007sp 282 89SF ELISA IgG 007sp ELISA IgG 95% CI of 007sp Туре concn (mcg/mL) concn (mcg/mL) IgG concn n 2 12.24 24.63 (21.25, 28.55) 260 9N 7.77 7.03 (5.52, 8.94) 247 1.75 8.51 17F (6.74, 10.73) 253 20A .55, 12.81) 250

	0.01	(01)
8.73	10.47	(8.

284

S

Table 2. Assigned values for 12 pneumococcal WHO QC serum samples as determined with the new pneumococcal reference

286 standard 007sp

	Assigned IgG value in mcg/mL (95% CI) for pneumococcal serotype:					
WHO						
Calibration						
Serum	2	9N	17F	20A		
730	24.14 (21.59, 27.00)	5.43 (4.83, 6.12)	6.72 (6.02, 7.49)	11.55 (10.16, 13.12)		
732	1.21 (1.08, 1.35)	2 (1.78, 2.26)	1.36 (1.22, 1.51)	6.17 (5.43, 7.01)		
736	45.05 (40.16, 50.55)	1.66 (1.48, 1.87)	9.65 (8.65, 10.77)	0.93 (0.82, 1.06)		
746	1.77 (1.58, 1.99)	8.05 (7.16, 9.06)	3.56 (3.19, 3.97)	1.56 (1.37, 1.77)		
754	18.43 (16.45, 20.64)	16.02 (14.23, 18.02)	3.62 (3.25, 4.04)	3.44 (3.03, 3.91)		
758	50.73 (44.88, 57.35)	3.12 (2.77, 3.51)	22.46 (19.98, 25.25)	5.76 (5.07, 6.55)		
760	112.91 (100.64, 126.67)	10.01 (8.89, 11.26)	22.37 (20.05, 24.95)	12.79 (11.26, 14.54)		
762	5.29 (4.72, 5.93)	0.88 (0.78, 0.98)	0.38 (0.34, 0.43)	29.56 (26.04, 33.56)		
768	2.45 (2.19, 2.74)	8.68 (7.71, 9.77)	1.04 (0.93, 1.16)	17.48 (15.38, 19.87)		
770	78.11 (69.62, 87.63)	13.44 (11.94, 15.12)	1.49 (1.34, 1.66)	167.72 (148.24, 189.75)		
772	33.05 (29.41, 37.15)	3.06 (2.72, 3.44)	21.36 (19.11, 23.87)	34.56 (30.45, 39.22)		
774	0.6 (0.53, 0.67)	1.82 (1.62, 2.05)	2.55 (2.29, 2.84)	1.48 (1.30, 1.68)		

n = \geq 27 for each estimate

288

289

S

290	Table 3. Comparison of ELISA concentrations between laboratories and laboratory-to-consensus assigned values for WHO QC sera ^a
291	

		Value for Laboratory:		
Laboratories	Statistic	LAB 1	LAB 2	LAB 3
LAB 1 (N=48)	Accuracy Coef (C _a) ^b	1	1	1
LAB 1	Pearson CC (r) ^b	1	0.993	0.998
LAB 1	Concordance CC (r _c) ^b	1	0.993	0.998
	CCC 95% CI		(0.988, 0.996)	(0.996, 0.999)
LAB 2 (N=48)	Accuracy Coef (C _a)		1	1
LAB 2	Pearson CC (r)		1	0.994
LAB 2	Concordance CC (r _c)		1	0.994
	CCC 95% CI			(0.989, 0.997
LAB 3 (N=48)	Accuracy Coef (Ca)			1
LAB 3	Pearson CC (r)			1
LAB 3	Concordance CC (r _c)			1
	CCC 95% CI			
Consensus Value (N=48)	Accuracy Coef (Ca)	1	1	1
	Pearson CC (r)	0.999	0.997	0.999
	Concordance CC (r _c)	0.999	0.997	0.999
	CCC 95% CI	(0.998, 0.999)	(0.995 <i>,</i> 0.999)	(0.998, 0.999

292 293

^a Consensus ELISA (log) concentrations were estimated within a serotype by use of a mixed-effects ANOVA model. Predicted ELISA

(log) concentrations were obtained for each laboratory by sample within a serotype for each of the replicate observations by use of a mixed-effects ANOVA model. Values in parentheses are 95% confidence intervals.


295

297 ^bC_a, accuracy coefficient, r, Pearson correlation coefficient, r_c, concordance correlation coefficient


Concentration








Pneumococcal Serotype



S



Lab